Detection of t(14;18), P53 and RAS gene mutations and quantification of residual disease in patients with B-cell non-Hodgkin's lymphoma

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 4, 2007, Pages 535-542

  Cikota, Bojana M ^a   Tukic Lj J ^a   Tarabar, O T ^b   Magic Z M ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b NONE

Author keywords

Minimal residual disease; Non Hodgkin's lymphoma; P53; Quantitative PCR; Ras genes; t(14; 18)

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; RAS PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INCIDENCE; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CHROMOSOME TRANSLOCATION 14; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE MUTATION; HEART; HUMAN; LUNG; MALE; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; FEMALE; GENES, P53; GENES, RAS; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; MUTATION; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; TRANSLOCATION, GENETIC;

EID: 38549099611     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Van Dongen J.J.M., Szczepańsky T., Pongres-Willemse MJ.: Detection of minimal residual disease in lymphoid malignancies. In: Deyos L., Linch D.C., Löwenberg B., eds. Textbook of malignant haematology. London: Martin Dunitz LTD, 1999: 685-724.
2. Faderl S., Kurzrock R., Estrov Z.: Minimal residual disease in hematologic disorders. Arch. Pathol. Lab. Med. 123: 1030-1034, 1999.
3. Provan D., Gribben J.G.: Detection of minimal residual disease in hematological malignancies. In: Provan D., Gribben J.G., eds. Molecular hematology, 2nd ed. Massachusetts: Blackwell Publishing, 2005: 53-89.
4. Hill M.E., MacLennan K.A., Cunningham D.C., et al.: Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study. Blood 88:1046-1051, 1996.
5. Solenthaler M., Matutes E., Brito-Babapulle V., Morula R., Catovsky C.: p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica 87:1141-1150, 2002.
6. Bea S., Lopez-Guillermo A., Ribas M., et al.: Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am. J. Pathol. 161:957-968, 2002.
7. Ortega M.M., Melo M.B., De Souza C.A., Loraand-Metze I., Costa F.F., Lima C.S.: A possible role of the P53 gene deletion as a prognostic factor in multiple myeloma. Ann. Hematol. 82: 405-409, 2003.
8. Beaupre D.M., Kurzrock R.: RAS and leukemia: From basic mechanisms to gene-directed therapy. J. Clin. Oncol. 3: 1071-1079, 1999.
9. Falini B., Mason D.Y.: Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: Clinical value of their detection by immunocytochemistry. Blood 99: 409-426, 2002.
10. Brisco M.J., Condon J., Hughes E., et al.: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343: 196-200, 1994.
11. Van Dongen J.J.M., Seriu T., Penzer-Grümayer R.E., et al.:Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352: 1731-1738, 1998.
12. Harris N.L., Jaffe E.S., Stein H., et al.: Revised European-American Classification of Lymphoid Neoplasms: A proposal from the International Lymphoma Study Group. Blood 84: 1361-1392, 1994.
13. Rosenberg S.A., Validity of the Ann Arbor staging classification for the non - Hodgkin's lymphomas. Cancer Treat. Rep. 61: 1023-1027, 1977.
14. Non - Hodgkin's lymphoma pathologic classification project. National Cancer Institute sponsored study of classification of non - Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 49: 2112-2135, 1982.
15. Cheson B.B., Bennett J.M., Grever M., et al.: National Cancer Institute - Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia: Revised guidelines for diagnosis and treatment. Blood 87: 4990-4997, 1996.
16. Wright D.K., Manos M.M.: Sample preparation from paraffin embeded tissues. In: Innis M.A., Gelfand D.H., Snisky J.J., White T.J., eds. PCR protocols: A guide to methods and applications. San Diego: Academic Press, 1990; 153-157.
17. Sambrook J., Fritsch E.F., Maniatis T.: Preparation of organic reagents. In: Nolan C, ed. Molecular cloning, a laboratory manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989; B4-B5.
18. Sykes P.J., Neoh S.H., Brisco M.J., Hughes E., Condon J., Morley A.A.: Quantitation of targets for PCR by use of limiting dilution. BioTechniques 13: 444-449, 1992.
19. Cikota B., Magić Z., Ilić V., Berger S., Stamatović D., Malešević M.: B-cell clonality assessment by polymerase chain reaction in patients with B-non Hodgkin's lymphomas. Balkan J. Med. Gen. 3: 31-35, 2000.
20. Dreger P., Ritgen M., Böttcher S., Schmitz N., Kneba M.: The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwile? Leukemia 19: 1135-1138, 2005.
21. Szczepański T., Willemse M.J., Brinkhof B., van Wering E.R., van der Burg M., van Dongen J.J.M.: Comparative analysis of IG and TCR gene rearrangements at diagnosis and at relapse of childhood precursor B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 99: 2315-2323, 2002.
22. Van Dongen J.J.M., Langerak A.W., Brüggemann M., et al.: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-396. Leukemia 17: 2257-2317, 2003.
23. Coustan-Smith E., Behm F.G., Sanchez J., et al.: Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 351: 550-554, 1998.
24. Scholten C., Fodinger M., Mitterbauer M., et al.: Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia. Ann. Hematol. 71: 155-160, 1995.
25. Brisco M.J., Hughes E., Neoh S.H., et al.: Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 12: 5251-5256, 1996.
26. Esteve J., Vilamor N., Colomer D., Cervantes F., Campo E., Carreras E., Monserrat E.: Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 15: 445-451, 2001.
27. Esteve J., Villamor N., Colomer D., Monserrat E., Rawstron A.C., Hillmen P.: Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. Blood 99: 1873-1874, 2002.
28. Petrovic A.S., Young R.L., Hilgarth B., Ambros P., Korsmeye P.J., Jaeger U.: The Ig heavy chain 3′ end confers a posttranskriptional processing advantage to bcl-2-IgH fusion RNA in t(14;18) lymphoma. Blood 91: 3952-61, 1997.
29. Sohn S.K., Jung J.T., Kim D.H., et al.: Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lumphoma. Am. J. Hematol. 73: 101-107, 2003.
30. Gascoyne R.D., Adomat S.A., Krajewski S., et al.: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1: 244-251, 1997.
31. Newcomb E.W.: P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk. Lymphoma. 17: 211-221, 1995.
32. Shaw G.R., Kronberger D.L.: TP53 deletions but not trisomy 12 are adverse in B-cell lymphopriliferative disorders. Cancer Genet. Cytogenet. 119: 146-154, 2000.
33. Konikova E., Kusenda J.: P53 protein expression in human leukemia and lymphoma cells. Neoplasma 48: 290-298, 2001.
34. Bezieau S., Devilder M.C., Avet-Losieau H., et al.: High incidence of N- and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat. 18: 212-224, 2001.
35. Corradini P., Ladetto M., Inghirami G., Boccadoro M., Pileri A.: N- and K-ras oncogenes in plasma cell dyscrasias. Leuk. Lymphoma 15: 17-20, 1994.
36. Corradini P., Ladetto M., Voena C., et al.: Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood 81: 2708-2713, 1993.
37. Szczepańsky T., Orfao A., van der Velden V.H.J., San Miguel J.F., van Dongen J.J.M.: Minimal residual disease in leukemia patients. Lancet 2: 409-417, 2001.
38. Van der Velden V.H.J., Hochhaus A., Gazzaniaga G., Szczepaňski T., Gabert J., van Dongen J.J.M.: Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 17: 1013-34, 2003.